ArticleFrontiers in nutrition2025
Tumour necrosis factor-
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart-failure (HF) survivors experience a disproportionate burden of incident malignancy, yet the biological bridge linking the two syndromes remains elusive. Tumour necrosis factor- Methods: In a retrospective hospital cohort, 415 clinically-stable adults ≥ 60 years with chronic HF were followed for a median of 5.2 years. Baseline TNF- Results: Sixty-two endpoint events (re-admission or follow-up visit at our hospital during which a tumour was detected) occurred (14.9%; 2,122 person-years). Cancer incidence rose step-wise across NIIS tertiles (7.2, 13.7, 23.9%; log-rank Conclusion: An elevated NIIS independently predicts our hospital-defined endpoint of tumour detection at re-admission/follow-up in older adults with HF and enhances risk stratification beyond conventional factors. Routine assessment of nutrient-inflammation crosstalk may enable targeted cardio-oncology surveillance and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.